Abstract
Aim: Trastuzumab prolongs progression-free and overall survival in HER2+ breast cancer (BC), but these are associated with increased distant recurrences and central nervous system metastases (CNSm). We retrospectively evaluated outcome and prognostic factors in CNSm and non-CNSm patients. Methods: Records of HER2+ BC treated in 2000-2017 were reviewed. Results: 283/1171 (24%) HER2+ BC patients developed metastatic disease. 109/283 patients (39%) have CNSm associated with worse prognosis and increased risk of death (hazard ratio: 4.7; 95% CI: 3.5-6.4). Prognostic factors were: number of CNSm (single vs multiple lesions; 3-year overall survival 39 vs 18%; p = 0.003); brain radiation (30 vs 14%; p < 0.001); new HER2-targeting therapies (30.6 vs 22.5%; p = 0.025). Conclusion: Prognosis of BC patients with CNSm has improved using HER2-targeting therapies but remains poor.
Original language | English |
---|---|
Pages (from-to) | 269-279 |
Number of pages | 11 |
Journal | Future oncology (London, England) |
Volume | 16 |
Issue number | 7 |
DOIs | |
Publication status | Published - Mar 2020 |
Keywords
- Adult
- Aged
- Aged, 80 and over
- Breast Neoplasms/metabolism
- Central Nervous System Neoplasms/diagnosis
- Combined Modality Therapy
- Female
- Humans
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Staging
- Patient Outcome Assessment
- Prognosis
- Receptor, ErbB-2/genetics
- Treatment Outcome